1
|
Ando K, Shimomura A, Watanabe K, Kunihisa T, Teruya K, Shimizu C. 441P Malignant diseases diagnosed in people living with HIV in Japan. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
2
|
Gennari A, Jackisch C, McCutcheon S, Flood E, Murali B, Guillaume X, Will O, Shimizu C, Mokiou S. 70P Factors influencing patient treatment decisions in early breast cancer (eBC): Discrete choice experiment (DCE) findings. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
3
|
Paluch-Shimon S, Neven P, Huober J, Cicin I, Jiang Z, Goetz M, Shimizu C, Huang C, Wei R, Nabinger S, Forrester T, Harbeck N. 63P Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2- high-risk early breast cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Burns JC, Hsieh LE, Kumar J, Behnamfar N, Shimizu C, Sivilay N, Tremoulet AH, Franco A. Characterization of circulating immune cells in acute Kawasaki disease suggests exposure to different antigens. Clin Exp Immunol 2020; 202:263-272. [PMID: 32812215 PMCID: PMC7670149 DOI: 10.1111/cei.13506] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Revised: 08/03/2020] [Accepted: 08/04/2020] [Indexed: 01/03/2023] Open
Abstract
Kawasaki disease (KD) is an acute pediatric vasculitis of unknown etiology that can cause coronary artery aneurysms, and is the leading cause of acquired heart disease in children. We studied aspects of the innate and adaptive immune response in 17 acute KD children prior to treatment with intravenous immunoglobulin. Distinct patterns within the innate immune response correlated with specific clinical features. Proinflammatory myeloid dendritic cells (mDC) were abundant in four of 17 (23·5%) subjects who were older and manifested severe inflammation with clinical myocarditis and elevated hepatobiliary enzyme levels. Of the nine subjects with low levels of anti‐inflammatory, tolerogenic mDC, six had enlarged cervical lymph nodes at diagnosis. In contrast, the adaptive immune repertoire varied greatly with no discernible patterns or associations with clinical features. Two subjects with aneurysms had numerous circulating CD8+ T cells. Ten subjects showed low CD4+ T cell numbers and seven subjects had CD4+ T cells in the normal range. CD4+ T cells expressed interleukin‐7 receptor (IL‐7R), suggesting repeated antigenic stimulation. Thymic‐derived regulatory T cells (nTreg) and peripherally induced regulatory T cells (iTreg) were also enumerated, with the majority having the nTreg phenotype. Natural killer (NK) and NK T cell numbers were similar across all subjects. Taken together, the results of the immune monitoring suggest that KD may have multiple triggers that stimulate different arms of the innate and adaptive compartment in KD patients. Thus, it is possible that diverse antigens may participate in the pathogenesis of KD.
Collapse
Affiliation(s)
- J C Burns
- School of Medicine, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA
| | - L E Hsieh
- School of Medicine, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA
| | - J Kumar
- School of Medicine, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA
| | - N Behnamfar
- School of Medicine, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA
| | - C Shimizu
- School of Medicine, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA
| | - N Sivilay
- School of Medicine, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA
| | - A H Tremoulet
- School of Medicine, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA
| | - A Franco
- School of Medicine, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA
| |
Collapse
|
5
|
Uneno Y, Sato K, Morita T, Nishimura M, Ito S, Mori M, Shimizu C, Horie Y, Hirakawa M, Nakajima TE, Tsuneto S, Muto M. Current status of integrating oncology and palliative care in Japan: a nationwide survey. BMC Palliat Care 2020; 19:12. [PMID: 31980015 PMCID: PMC6982384 DOI: 10.1186/s12904-020-0515-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2019] [Accepted: 01/13/2020] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Palliative care (PC) is increasingly recognized as essential for oncology care, and several academic societies strongly recommend integrating oncology and palliative care (IOP) in daily practice. Similarly, the Japanese government encouraged the implementation of IOP through the Cancer Control Act of 2007; however, its detailed progress remains unclear. Therefore, this cross-sectional nationwide survey was conducted to investigate the current status and hospital executive physicians' perception of IOP. METHODS The questionnaire was developed based on IOP indicators with international consensus. It was distributed to executive physicians at all government-designated cancer hospitals (DCHs, n = 399) and matched non-DCHs (n = 478) in November 2017 and the results were compared. RESULTS In total, 269 (67.4%) DCHs and 259 (54.2%) non-DCHs responded. The number of PC resources in DCHs was significantly higher than those in non-DCHs (e.g., full-time PC physicians and nurses, 52.8% vs. 14.0%, p < 0.001; availability of outpatient PC service ≥3 days per week, 47.6% vs. 20.7%, p < 0.001). Routine symptom screening was more frequently performed in DCHs than in non-DCHs (65.1% vs. 34.7%, p < 0.001). Automatic trigger for PC referral availability was limited (e.g., referral using time trigger, 14.9% vs. 15.3%, p = 0.700). Education and research opportunities were seriously limited in both types of hospitals. Most executive physicians regarded IOP as beneficial for their patients (95.9% vs. 94.7%, p = 0.163) and were willing to facilitate an early referral to PC services (54.7% vs. 60.0%, p < 0.569); however, the majority faced challenges to increase the number of full-time PC staff, and < 30% were planning to increase the staff members. CONCLUSIONS This survey highlighted a considerable number of IOP indicators met, particularly in DCHs probably due to the government policy. Further efforts are needed to address the serious research/educational gaps.
Collapse
Affiliation(s)
- Y Uneno
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawaharacho Shogoin Sakyo-ku, Kyoto, 606-8507, Japan. .,Seirei Hospice, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
| | - K Sato
- Department of Nursing, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Morita
- Division of Supportive and Palliative Care, Seirei Mikatahara General Hospital, Hamamatsu, Japan
| | - M Nishimura
- Geriatric Health Service Facility, You-You no Sono, Hiroshima, Japan.,Department of Health Informatics, Kyoto University Graduate School of Medicine/ School of Public Health, Kyoto, Japan
| | - S Ito
- Department of Health Informatics, Kyoto University Graduate School of Medicine/ School of Public Health, Kyoto, Japan
| | - M Mori
- Palliative Care Team, Seirei Mikatahara General Hospital, Hamamatsu, Japan
| | - C Shimizu
- Department of Breast Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan
| | - Y Horie
- Department of Clinical Oncology, St Marianna University School of Medicine, Kawasaki, Japan
| | - M Hirakawa
- Department of Clinical Oncology, St Marianna University School of Medicine, Kawasaki, Japan
| | - T E Nakajima
- Department of Clinical Oncology, St Marianna University School of Medicine, Kawasaki, Japan
| | - S Tsuneto
- Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - M Muto
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawaharacho Shogoin Sakyo-ku, Kyoto, 606-8507, Japan
| |
Collapse
|
6
|
Sawaki M, Yamada A, Kumamaru H, Miyata H, Shimizu C, Miyashita M, Honma N, Taira N, Saji S. Elderly patients in the Japanese breast cancer registry. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Mota B, Reis Y, Doria M, Ricci M, Shimizu C, Ferreira V, Tucunduva T, de Barros N, Baracat E, Filassi J. Brazilian randomized study: Impact of preoperative magnetic resonance in the evaluation for breast cancer conservative surgery (BREAST-MRI Trial). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz098.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Yu U, Sato K, Morita T, Mori M, Shimizu C, Horie Y, Hirakawa M, Nakajima T, Tsuneto S, Muto M. Current status of the integration of oncology and palliative care in Japan: A nationwide survey. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy295.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Yu U, Sato K, Morita T, Mori M, Shimizu C, Horie Y, Hirakawa M, Nakajima T, Tsuneto S, Muto M. Perspectives and attitudes towards the integration of oncology and palliative care in Japan: A nationwide survey. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy295.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Kawachi A, Shimomura A, Matsuzaki J, Kawauchi J, Takizawa S, Sakamoto H, Shimizu C, Tamura K, Ochiya T. Prediction of response to trasutuzumab/pertuzumab/taxane therapy by microRNA in HER2 positive advanced breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy047.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Dória MT, Mota BS, Reis YN, Ricci MD, Piato JRM, Ferreira VCCS, Shimizu C, Barros N, Filassi JR, Baracat EC. Abstract OT2-02-01: Brazilian randomized study - Impact of preoperative magnetic resonance in the evaluation for breast cancer conservative surgery (BREAST-MRI trial). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot2-02-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A precise preoperative evaluation of the tumor is essential to improve breast cancer surgical management. Currently, mammography associated with ultrasound and clinical exam are the standard techniques for evaluating extension and tumor localization. However, approximately one third of the lesions in patients eligible for conservative surgical treatment are misevaluated by these methods. Breast magnetic resonance imaging (MRI) has a high sensitivity (95-100%) in detecting invasive neoplasms, and is able to detect occult tumors, multifocal and/or multicentric disease, and contralateral breast cancer more accurately than mammography and ultrasound. Until now, there are only three randomized trials assessing the role of preoperative MRI. These trials have different designs and contradictory results. Trial design: BREAST-MRI is a randomized, open label, unblinded trial designed to compare the accuracy of breast MRI in the preoperative planning of surgical treatment of breast cancer to standard protocol (clinical exam of the breast, mammography and/or breast ultrasound) and the impact of breast MRI on breast cancer outcome. Patients are randomized on a 1:1 basis, stratified for mammary density, into two groups: 1)MRI group: patients are submitted to MRI and standard protocol 2)Control group: standard protocol. First phase: patient recruitment and data collection up until surgery. Second phase: follow-up for five years or until death. Eligibility criteria: women aged 18 years or older with breast cancer stages I to III candidates for conservative surgery (CC). Specific aims: The aim of this study is to evaluate the ability of MRI in selecting patients for conservative treatment of breast cancer. Primary outcomes are: false positive rates, false negative rates, positive predictive value and negative predictive value of MRI in breast cancer CC. Secondary outcomes are: rates of positive margins on pathological examination; reoperation rates; number of conversions to mastectomy; accuracy of MRI according to mammographic density, immunohistochemical subtype and histopathology of the tumor; rates of multicentricity, multifocality and bilateralality of tumors; disease-free survival after 3 and 5 years; and cost-effectiveness of breast MRI. Statistical methods: The calculated total case number for this trial is 372, assuming a recurrence rate of 10% for CC and 1% for mastectomies. The Shapiro-Whilks test will be used to verify if distribution of the quantitative variables follows normal distribution. The baseline population will be analyzed using the t-Student test, or the Mann-Whitney test when appropriate. To test the existence of a possible association between outcomes and the categorized characteristics, chi-square and Fisher's exact test will be performed. Disease progression will be reassessed at 3 and 5 years follow-up, in order to produce a log-rank Kaplan-Meier curve of survival. Present accrual and target accrual: In June 2017, randomizations are at approximately 90% of the target sample size.
Citation Format: Dória MT, Mota BS, Reis YN, Ricci MD, Piato JRM, Ferreira VCCS, Shimizu C, Barros N, Filassi JR, Baracat EC. Brazilian randomized study - Impact of preoperative magnetic resonance in the evaluation for breast cancer conservative surgery (BREAST-MRI trial) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT2-02-01.
Collapse
Affiliation(s)
- MT Dória
- State University of Campinas, Campinas, Sao Paulo, Brazil; University of São Paulo, Sao Paulo, Brazil
| | - BS Mota
- State University of Campinas, Campinas, Sao Paulo, Brazil; University of São Paulo, Sao Paulo, Brazil
| | - YN Reis
- State University of Campinas, Campinas, Sao Paulo, Brazil; University of São Paulo, Sao Paulo, Brazil
| | - MD Ricci
- State University of Campinas, Campinas, Sao Paulo, Brazil; University of São Paulo, Sao Paulo, Brazil
| | - JRM Piato
- State University of Campinas, Campinas, Sao Paulo, Brazil; University of São Paulo, Sao Paulo, Brazil
| | - VCCS Ferreira
- State University of Campinas, Campinas, Sao Paulo, Brazil; University of São Paulo, Sao Paulo, Brazil
| | - C Shimizu
- State University of Campinas, Campinas, Sao Paulo, Brazil; University of São Paulo, Sao Paulo, Brazil
| | - N Barros
- State University of Campinas, Campinas, Sao Paulo, Brazil; University of São Paulo, Sao Paulo, Brazil
| | - JR Filassi
- State University of Campinas, Campinas, Sao Paulo, Brazil; University of São Paulo, Sao Paulo, Brazil
| | - EC Baracat
- State University of Campinas, Campinas, Sao Paulo, Brazil; University of São Paulo, Sao Paulo, Brazil
| |
Collapse
|
12
|
Sudo K, Ohtake Y, Nishikawa T, Uehara T, Shimizu H, Ishikawa M, Kato T, Shimomura A, Noguchi E, Yonemori K, Shimizu C, Tamura K. Outcomes of paclitaxel and ifosfamide following surgery for early and advanced stage uterine carcinosarcoma: A single institution experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx663.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
13
|
Seo T, Shimoi T, Hamada A, Shimomura A, Sudo K, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. The frequency of somatic AKT1 mutation among Japanese breast and endometrial cancer patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx653.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Iizumi S, Shimomura A, Shimoi T, Sudo K, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Impact of perioperative fluoropyrimidines on the efficacy of capecitabine in patients with advanced breast cancer: A retrospective study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx654.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
15
|
Shimomura A, Yonemori K, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Shimizu C, Tamura K, Fujiwara Y. Gene alteration in triple negative breast cancer patients in a phase I/II study of combination therapy with eribulin and olaparib. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, Shimomura A, Yunokawa M, Yonemori K, Shimizu C, Hamada A, Kanayama Y, Watanabe Y, Fujiwara Y, Tamura K. 64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer. Ann Oncol 2017; 28:2028-2029. [PMID: 28505219 DOI: 10.1093/annonc/mdx227] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- S Sasada
- Department of Breast and Medical Oncology
| | | | | | - M Yoshida
- Department of Pathology and Clinical Laboratories, National Cancer Center Hospital
| | - N Honda
- Department of Diagnostic Radiology
| | - T Shimoi
- Department of Breast and Medical Oncology
| | | | - M Yunokawa
- Department of Breast and Medical Oncology
| | - K Yonemori
- Department of Breast and Medical Oncology
| | - C Shimizu
- Department of Breast and Medical Oncology
| | - A Hamada
- Division of Molecular Pharmacology and Pharmacokinetics, National Cancer Center Research Institute, Tokyo
| | - Y Kanayama
- RIKEN Center for Life Science Technologies, Hyogo, Japan
| | - Y Watanabe
- RIKEN Center for Life Science Technologies, Hyogo, Japan
| | - Y Fujiwara
- Department of Breast and Medical Oncology
| | - K Tamura
- Department of Breast and Medical Oncology
| |
Collapse
|
17
|
Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Shimizu C, Takeshita F, Niida S, Kinoshita T, Tamura K, Ochiya T. Abstract P4-07-04: Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-07-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
[Background] It is recently reported that microRNAs (miRNAs) are stably present in serum and potentially useful in the diagnosis and evaluation of treatment of cancer.
[Materials and Methods] Serum samples of breast cancer before treatment (n=1280) between 2008 and 2014 were obtained from National Cancer Center Hospital and controls (n=3348) were obtained from collaborative institutes. Additionally, the serum sample of patients who received neoadjuvant chemotherapy (NAC) and surgery between last chemotherapy administration and surgery were collected. A comprehensive quantitative expression analysis of miRNA was performed using the by DNA chip “3D-Gene® (Toray Industries Inc.)” Clinicopathological data was retrieved from medical records. Pathological complete response (pCR) was defined as the absence of residual invasive and in situ cancer of the resected breast specimen and all sampled regional lymph nodes.
[Results] Serum samples before treatment of breast cancer patients (n=74), non-cancer controls and patients with other cancers were used (n=2007) in a training set. The rest except for samples after NAC were used in a test set. The formula with the combination of five miRNAs (miR-1246, miR-1307-3p, miR-4634, miR-6861-5p, and miR-6875-5p) was found to be able to detect breast cancer (BCmiR set). BCmiR set had a sensitivity of 97.3%, specificity of 82.9% and accuracy of 89.7% in the test cohort. BCmiR set could detect breast cancer in the non-invasive stage (sensitivity of 98.0% for Tis).
In the breast cancer patients, 91 patients received NAC and surgery. Median age of NAC patients was 49 years (range 28-77). Forty-two patients were hormone receptor-positive (HR+) and HER2-negative (HER2-), 24 were HR+ and HER2-positive (HER2+), 11 were hormone receptor-negative (HR-) and HER2+ and 14 were HR- and HER2-. pCR was observed in 19 (20.9%) of NAC patients. pCR in each subtypes were 3 (7.7%) in HR+ and HER2-, 6 (33.3%) in HR+ and HER2+, 4 (57.1%) in HR- and HER2+ and 3 (27.3%) in HR- and HER2-. Serum after NAC were obtained from 19 pCR patients and 71 non-pCR patients. When we applied BCmiR set to the serum samples after NAC, the average diagnostic index (cut-off value=0) in pCR patients was significantly lower than that in non-pCR patients (pCR, -0.30±0.84; non-pCR, 0.31±1.15; p=0.03). In fact, 57.9% of pCR patients were classified into non-breast cancer. However, 40.8% of non-pCR patients were misclassified into non-breast cancer.
[Conclusion] The combination of five miRNAs (BCmiR set) measured from serum can be used to detect breast cancer. BCmiR set has potential to predict pCR in patients who received NAC. The further analysis to predict pCR is underway and further results will be presented in the symposium.
Citation Format: Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Shimizu C, Takeshita F, Niida S, Kinoshita T, Tamura K, Ochiya T. Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-07-04.
Collapse
Affiliation(s)
- A Shimomura
- National Cancer Center Hospital, Tokyo, Japan; Toray Industries, Inc., Kamakura, Japan; National Cancer Center Research Institute, Tokyo, Japan; National Center for Geriatrics and Gerontology, Nagoya, Japan
| | - S Shiino
- National Cancer Center Hospital, Tokyo, Japan; Toray Industries, Inc., Kamakura, Japan; National Cancer Center Research Institute, Tokyo, Japan; National Center for Geriatrics and Gerontology, Nagoya, Japan
| | - J Kawauchi
- National Cancer Center Hospital, Tokyo, Japan; Toray Industries, Inc., Kamakura, Japan; National Cancer Center Research Institute, Tokyo, Japan; National Center for Geriatrics and Gerontology, Nagoya, Japan
| | - S Takizawa
- National Cancer Center Hospital, Tokyo, Japan; Toray Industries, Inc., Kamakura, Japan; National Cancer Center Research Institute, Tokyo, Japan; National Center for Geriatrics and Gerontology, Nagoya, Japan
| | - H Sakamoto
- National Cancer Center Hospital, Tokyo, Japan; Toray Industries, Inc., Kamakura, Japan; National Cancer Center Research Institute, Tokyo, Japan; National Center for Geriatrics and Gerontology, Nagoya, Japan
| | - C Shimizu
- National Cancer Center Hospital, Tokyo, Japan; Toray Industries, Inc., Kamakura, Japan; National Cancer Center Research Institute, Tokyo, Japan; National Center for Geriatrics and Gerontology, Nagoya, Japan
| | - F Takeshita
- National Cancer Center Hospital, Tokyo, Japan; Toray Industries, Inc., Kamakura, Japan; National Cancer Center Research Institute, Tokyo, Japan; National Center for Geriatrics and Gerontology, Nagoya, Japan
| | - S Niida
- National Cancer Center Hospital, Tokyo, Japan; Toray Industries, Inc., Kamakura, Japan; National Cancer Center Research Institute, Tokyo, Japan; National Center for Geriatrics and Gerontology, Nagoya, Japan
| | - T Kinoshita
- National Cancer Center Hospital, Tokyo, Japan; Toray Industries, Inc., Kamakura, Japan; National Cancer Center Research Institute, Tokyo, Japan; National Center for Geriatrics and Gerontology, Nagoya, Japan
| | - K Tamura
- National Cancer Center Hospital, Tokyo, Japan; Toray Industries, Inc., Kamakura, Japan; National Cancer Center Research Institute, Tokyo, Japan; National Center for Geriatrics and Gerontology, Nagoya, Japan
| | - T Ochiya
- National Cancer Center Hospital, Tokyo, Japan; Toray Industries, Inc., Kamakura, Japan; National Cancer Center Research Institute, Tokyo, Japan; National Center for Geriatrics and Gerontology, Nagoya, Japan
| |
Collapse
|
18
|
Takahiro E, Yunokawa M, Yoshida H, Bun S, Shimoi T, Shimomura A, Noguchi E, Kodaira M, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Tamura K. The prognostic impact of the pathological response to neoadjuvant dose-dense therapy for ovarian carcinoma. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30394-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
19
|
Ohtake Y, Nishikawa T, Yoshida H, Ishikawa M, Ikeda S, Kato T, Shimomura A, Shimoi T, Noguchi E, Yonemori K, Shimizu C, Yunokawa M, Tamura K. 320P Adjuvant chemotherapy comprising a paclitaxel and carboplatin regimen or paclitaxel and ifosfamide regimen for uterine carcinosarcoma, a single institutional retrospective study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw585.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Shimoi T, Hamada A, Kitamura Y, Nishijo T, Shimomura A, Shimizu C, Yoshida M, Kinoshita T, Fujiwara Y, Tamura K. 33P Somatic mutations of PIK3CA and AKT1 in Japanese breast cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw574.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Im SA, Mukai H, Park I, Masuda N, Shimizu C, Kim S, Im YH, Ohtani S, Bartlett C, Lu D, Mori A, Gauthier E, Finn R, Toi M. 116O Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor-positive (ER +)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw577] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Takehara Y, Yunokawa M, Sasada S, Noguchi E, Shimomura A, Shimoi T, Yonemori K, Shimizu C, Kato T, Tamura K. 321P Clinical course comparison between patients with type 1 and type 2 uterine endometrial cancers. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw585.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
23
|
Nishikawa T, Yonemori K, Kitano A, Shimoi T, Noguchi E, Yunokawa M, Shimizu C, Fujiwara Y, Yoshida A, Kobayashi E, Nakatani F, Kawai A, Chuman H, Koyama T, Shimomura A, Kitano S, Shimizu T, Fujiwara Y, Yamamoto N, Tamura K. 511P Retrospective study of sarcoma in practical and developmental therapeutics in Japan. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00669-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
24
|
Inagaki C, Shimoi T, Okuma H, Kawachi A, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. 510P Safety and efficacy of eribulin mesylate in patients with advanced soft tissue sarcoma in daily practice. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00668-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
25
|
Ohtake Y, Nishikawa T, Yoshida H, Ishikawa M, Ikeda S, Kato T, Shimomura A, Shimoi T, Noguchi E, Yonemori K, Shimizu C, Yunokawa M, Tamura K. 320P Adjuvant chemotherapy comprising a paclitaxel and carboplatin regimen or paclitaxel and ifosfamide regimen for uterine carcinosarcoma, a single institutional retrospective study. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00478-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
26
|
Kodaira M, Yonemori K, Shimoi T, Shimomura A, Yunokawa M, Shimizu C, Fujiwara Y, Tamura K. 576P Wilms tumor gene (WT-1) expression in female patients with unfavorable subset of cancer of unknown primary site. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw603.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Oshiro Y, Shimoi T, Okuma H, Kawai A, Shimomura A, Noguchi E, Yunokawa M, Shimizu C, Yonemori K, Fujiwara Y, Tamura K. 518P Feasibility and outocome of adult patients with osteosarcoma of the jaws. A single institute experience-. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw597.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Noguchi E, Yonemori K, Shimoi T, Yunokawa M, Okuma H, Kawachi A, Kitano A, Nishikawa T, Shimomura A, Shimizu C, Takiguchi Y, Kawai A, Fujiwara Y, Tamura K. 154P Clinical trial designs for the approval of rare cancer drugs in Japan. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw579.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Shimoi T, Hamada A, Kitamura Y, Nishijo T, Shimomura A, Shimizu C, Yoshida M, Kinoshita T, Fujiwara Y, Tamura K. 33P Somatic mutations of PIK3CA and AKT1 in Japanese breast cancer. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00193-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
30
|
Inagaki C, Shimoi T, Okuma H, Kawachi A, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. 510P Safety and efficacy of eribulin mesylate in patients with advanced soft tissue sarcoma in daily practice. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw597.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Nishikawa T, Yonemori K, Kitano A, Shimoi T, Noguchi E, Yunokawa M, Shimizu C, Fujiwara Y, Yoshida A, Kobayashi E, Nakatani F, Kawai A, Chuman H, Koyama T, Shimomura A, Kitano S, Shimizu T, Fujiwara Y, Yamamoto N, Tamura K. 511P Retrospective study of sarcoma in practical and developmental therapeutics in Japan. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw597.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Oshiro Y, Shimoi T, Okuma H, Kawai A, Shimomura A, Noguchi E, Yunokawa M, Shimizu C, Yonemori K, Fujiwara Y, Tamura K. 518P Feasibility and outocome of adult patients with osteosarcoma of the jaws. A single institute experience-. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00676-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
33
|
Tsushita N, Shimoi T, Okuma H, Kawachi A, Kitano A, Nishikawa T, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. 118P A retrospective comparison of eribulin and capecitabine in patients with HER2-negative metastatic breast cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw577.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Ebata T, Yunokawa M, Bun S, Noguchi E, Shimomura A, Shimoi T, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Tamura K. 312P Elevated serum CA125 predicts recurrence in patients with completely resected ovarian clear cell carcinoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw585.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Kodaira M, Yonemori K, Shimoi T, Shimomura A, Yunokawa M, Shimizu C, Fujiwara Y, Tamura K. The prognostic impact of the putative primary site of breast and ovarian cancers in an unfavorable subset of cancer of unknown primary site. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw393.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Matsumoto K, Tamura K, Yoshida H, Nishikawa T, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Hashiba H, Kiriyama T, Leahy T, Shepherd S, Fujiwara K. A phase 1 study of single agent veliparib in Japanese subjects with advanced solid tumors. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw374.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Nishikawa T, Yonemori K, Okuma H, Kawachi A, Kitano A, Shimoi T, Shimomura A, Noguchi E, Yunokawa M, Yoshida H, Shimizu C, Fujiwara Y, Tamura K. Overxpression of HER2/neu in uterine carcinosarcoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw374.43] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
38
|
Tanabe Y, Shiraishi S, Nishizawa D, Hamada A, Hasegawa J, Ozaki Y, Tamura N, Shimomura A, Yunokawa M, Yonemori K, Takano T, Kawabata H, Ikeda K, Tamura K, Fujiwara Y, Shimizu C. Paclitaxel-induced sensory peripheral neuropathy is associated with a SCN9A variant. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Tamura K, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Fujisaki Y, Yver A, Doi T. Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.07] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Kobayashi T, Nakano K, Tomomatsu J, Nara E, Ito Y, Kobayashi K, Fukada I, Araki K, Shimomura A, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Nakamura K, Kotani N, Inatani M, Tamura K, Takahashi S. Abstract P3-14-10: Phase Ia/Ib study of taselisib (GDC-0032), a potent and selective phosphoinositide 3-kinase inhibitor, in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer (JO29196 study). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-14-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Taselisib (GDC-0032) is an orally bioavailable, potent and selective phosphoinositide 3-kinase (PI3K) inhibitor. Preclinical data showed that taselisib had increased antitumor activity against PIK3CA (gene encoding the PI3Kα isoform) mutant tumors. This study aimed to investigate the safety, tolerability and pharmacokinetics (PK) of taselisib as monotherapy and in combination with fulvestrant in Japanese patients (pts).
Materials and methods:
A 3+3 design was used. In Phase Ia, pts with advanced solid tumors received taselisib tablet monotherapy (2, 4 or 6 mg once daily [QD]), and safety and PK were evaluated. In Phase Ib, pts with hormone receptor-positive locally advanced or metastatic breast cancer received taselisib (2 or 4 mg QD) in combination with fulvestrant (500 mg at a time), and safety and PK were evaluated. Maximal administered doses of 6 mg QD as a single agent and 4 mg QD in combination with fulvestrant were based upon prior clinical trial experience with taselisib (Juric D. et al. AACR 2013, Abstract LB-64; Juric D. et al. SABCS 2013, Abstract PD1-3).
Results:
As of 15 Mar 2015, 9 pts (PIK3CA mutant: 2 pts) were enrolled in Phase Ia and 3 pts in Phase Ib. Phase Ia dose-escalation study has been completed and Phase Ib is ongoing.
In Phase Ia, no dose-limiting toxicity (DLT) was observed at any dose level tested (maximum administered dose of 6 mg QD). Common (≥3 pts) adverse reactions (ARs) were stomatitis (4 pts), rash (3 pts) and diarrhea (3 pts); the only Grade ≥3 AR was neutropenia (1 pt). Partial response was observed in 1 pt who received taselisib 4 mg and had a PIK3CA mutant breast tumor. Stable disease was observed in 4 pts. Cmax and AUC indicated a dose-proportional PK profile of taselisib within the dose range tested. Moreover, taselisib PK in Japanese pts was consistent with the PK reported from North American and European pts (Juric D. et al. AACR 2013, Abstract LB-64).
In Phase Ib, 3 pts received taselisib 2 mg in combination with fulvestrant and no DLT was observed. Preliminary ARs were similar to those with monotherapy and no Grade ≥3 AR was reported. Confirmation of tolerability of taselisib 4 mg in combination with fulvestrant is under evaluation.
Conclusion:
Taselisib monotherapy was well tolerated in Japanese pts up to a dose of 6 mg, which is the recommended dose in non-Japanese pts. Promising preliminary activity of monotherapy was observed in advanced solid tumors, especially in a pt with PIK3CA mutant tumor. The combination of taselisib 2 mg with fulvestrant is well tolerated. Investigation of tolerability of taselisib 4 mg in combination with fulvestrant is ongoing. Final results of this study will be presented here at the Symposium this year.
Citation Format: Kobayashi T, Nakano K, Tomomatsu J, Nara E, Ito Y, Kobayashi K, Fukada I, Araki K, Shimomura A, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Nakamura K, Kotani N, Inatani M, Tamura K, Takahashi S. Phase Ia/Ib study of taselisib (GDC-0032), a potent and selective phosphoinositide 3-kinase inhibitor, in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer (JO29196 study). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-14-10.
Collapse
Affiliation(s)
- T Kobayashi
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Nakano
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - J Tomomatsu
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - E Nara
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - Y Ito
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Kobayashi
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - I Fukada
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Araki
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - A Shimomura
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - T Shimoi
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - M Kodaira
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - M Yunokawa
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Yonemori
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - C Shimizu
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Nakamura
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - N Kotani
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - M Inatani
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Tamura
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - S Takahashi
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| |
Collapse
|
41
|
Nishikawa T, Tanabe Y, Tsuda H, Yoshida M, Shimoi T, Shimomura A, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. 66P Predictive markers of clinical progressive disease during neoadjuvant chemotherapy in early triple negative breast cancers. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv519.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Kawachi A, Okochi-Takada E, Shimoi T, Shimomura A, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Ushijima T, Tamura K. 98P BRCA1 methylation in triple-negative breast cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv519.47] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Kodaira M, Yonemori K, Yoshida A, Shimoi T, Shimomura A, Yunokawa M, Shimizu C, Fujiwara Y, Tamura K. 445 Clinical utility of chemotherapy based on the estimated primary organ in patients with cancer of unknown primary site. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30279-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
44
|
Sasada S, Kodaira M, Shimoi T, Shimomura A, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. 3433 Peripheral neuropathy caused by vincristine-containing chemotherapy for adult soft tissue sarcoma: A comparison between young and older adults. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31906-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
45
|
Ling L, Bulik D, Duffner J, Shimizu C, Sarvaiya H, Kapoor B, Brown J, Markowitz L, Arevalo E, Schultes B, Capila I, Saldova R, Stockmann H, Albrecht S, McManus C, Rudd P, Kaudinya G, Manning A, Tremoulet A, Bosques C, Burns J. OP0197 High-Resolution, Integrated Molecular Profiling Reveals Persistent Inflammation in Kawasaki Disease Patients with Coronary Artery Aneurysms. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
46
|
Abstract
Proliferation and differentiation of the epidermis in organ culture of adult human skin by the sponge matrix method were studied histologically and autoradiographically, and the following results were obtained: 1) On the first day of culture, mitotic figures were already observable in the epidermis. The outgrowth of epidermal cells at the margins of the explants started. On the second day, there was transformation to a zone that will be referred to as the newly formed stratum corneum in the upper epidermis. 2) On the third and fourth days, the increased growth of epidermal cells caused thickening of the epidermis. Simultaneously, Malpighian cells progressively differentiated into a cornified layer. 3) On and after the fifth day, the basospinous cell layer was reduced in thickness in most of explants. On the ninth and tenth days, DNA synthesis in the basal layer was still obvious, although the epidermis showed a thickness of only one or two cells overlaid with a large number of horny layers. 4) In the culture medium supplemented with corticosteroid, the epidermal growth was slightly depressed with lessened formation of stratum corneum in the early stages of culture as compared with the explants cultured in the basic medium. The reduction of the basospinous layer was scarcely notable after the fifth day. Even after 10-11 days, epidermal cells were well preserved and their stratified squamous architecture was less disorganized. It seemed that corticosteroid could prolong the survival of adult human skin in vitro. These findings indicate that this culture technique could be used as a model for organ culture of adult human skin.
Collapse
Affiliation(s)
- H Yasuno
- Department of Dermatology, Kyoto Prefectural University of Medicine, Kawara-machi, Hirokoji, Kamikyo-ku, Kyoto, Japan
| | | | | | | | | | | | | |
Collapse
|
47
|
Hironaka A, Tsuda H, Yoshida M, Shimizu C, Tamura K, Fujiwara Y, Hojo T, Kinoshita T, Maeshima A, Hiraoka N. P019 Histopathological features of operable breast cancer detected in women younger than 35 years. Breast 2015. [DOI: 10.1016/s0960-9776(15)70069-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
48
|
Tanabe Y, Tsuda H, Yoshida M, Kinoshita T, Kodaira M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. P025 Immunological factors to predict disease progression during neoadjuvant chemotherapy. Breast 2015. [DOI: 10.1016/s0960-9776(15)70075-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
49
|
Bando H, Ohno S, Kato T, Tamura N, Asada Y, Watanabe C, Tsugawa K, Suzuki N, Shimizu C. PO33 Clinical practice guideline for preservation of fertility in breast cancer patients in Japan. Breast 2014. [DOI: 10.1016/s0960-9776(14)70043-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
50
|
Tanaka R, Yonemori K, Hirakawa A, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K. Risk Factors for Developing Skeletal-Related Events Associated with Metastatic Breast Cancer Patients Receiving Bone-Modifying Agents. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu329.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|